Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LGBTQ+

New DH permanent secretary

The Department of Health has appointed Una O'Brien as permanent secretary, with responsibilities including the management of healthcare reforms

NHS reforms face growing criticism

Shadow health secretary condemns 'bad deal' as BMA withdraws support

Quarter of doctors use online network daily

Online network Doctors.net.uk is witnessing record levels of engagement with doctors and has seen more than 40,000 unique users a day

New campaign to promote cancer check-ups

The UK's Department of Health has announced a new campaign to alert people to early signs of cancer and encourage check-ups

Former BMA chair to face disciplinary panel

Former chairman of the British Medical Association, James Johnson, is due to appear before a disciplinary panel accused of professional misconduct

SMC approves Glivec for GIST

Glivec has been approved for use within NHS Scotland as adjuvant post-surgery therapy to delay the recurrence of GIST

SMC approves Multaq, recommends Nexium

The Scottish Medicines Consortium has approved S-A's Multaq for use and issued a positive recommendation on AZ's Nexium sachets for children

Draft NICE guidance rejects GSK’s Revolade

Draft guidance from the UK's NICE has not recommended GSK's Revolade for chronic immune thrombocytopenic purpura

NICE approves RoActemra and MTX for RA

NICE has approved RoActemra plus methotrexate for use in rheumatoid patients who have failed or cannot take MabThera

NICE rejects Novartis’ Glivec for GIST

NICE has issued final guidance ruling against the use of Glivec as an adjuvant treatment following the removal of a gastrointestinal stromal tumour

NICE recommends multiple myeloma drugs

The National Institute for Health and Clinical Excellence has issued draft guidance recommending bortezomib and thalidomide for multiple myeloma

Multaq given restricted NICE approval

After rejecting the drug earlier this year, the UK's NICE has given sanofi-aventis's Multaq limited approval as a second-line treatment for atrial fibrillation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links